Wellington-based cancer software company Volpara Health Technologies is calling new European breast density screening guidelines an “incredible step forward” for women in the region, and a significant market opportunity for the ASX-listed company.
Volpara founder/chief executive Ralph
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
